Circulating malondialdehyde modified LDL is a biochemical risk marker for coronary artery disease

Amaki, Toshihiro; Suzuki, Toru; Nakamura, Fúmitaka; Hayashi, Doubun; Imai, Yumi; Morita, Hiroyuki; Fukino, Keiko; Nojiri, Takefumi; Kitano, Shouichi; Hibi, Nozomu; Yamazaki, Tsutomu; Nagai, Ryozo

doi:10.1136/hrt.2003.018226

Cited by 55 publications

(39 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To this end, the authors have made efforts in developing stratifying biomarkers to aid in the diagnostic and prognostic assessment of coronary artery disease which have included copeptin, [4] proenkephalin (PENK), [5] mid-regional pro-adrenomedullin (MR-proADM), [6] pro-substance P (pro-SP), [7] oxidized low density lipoprotein (oxidized phosphatidylcholine, malondialdehyde-modified) [8,9] and molecular forms of natriuretic peptide. [10] Aside from the traditional protein-based biomarkers discussed above, newer metabolite-based biomarkers are a topic of recent interest.…”

Section: Introductionmentioning

confidence: 99%

Trimethylamine N-oxide and Risk Stratification after Acute Myocardial Infarction

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Trimethylamine N-oxide and Risk Stratification after Acute Myocardial Infarction

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Circulating levels of MDA-LDL were higher in patients with than without coronary artery disease 20,21) ; however, the MDA-LDL level is not related to traditional risk factors, including smoking, but is independently related to coronary artery disease 21) . Recently, two novel, oxidatively modified LDL markers have been identified 12,22) .…”

Section: Introductionmentioning

confidence: 99%

α1-Antitrypsin Low-Density-Lipoprotein Serves as a Marker of Smoking-Specific Oxidative Stress

Wada

Ura

Satoh‐Asahara

et al. 2012

JAT

View full text Add to dashboard Cite

Aim: While smoking cessation (SC) leads to a reduction of cardiovascular events, atherogenic biomarkers specifically connected with cigarette smoking and SC are unknown. Circulating levels of oxidatively modified low-density-lipoprotein (LDL) are associated with a high risk of cardiovascular diseases. Recently, two novel, oxidatively modified LDL markers, serum amyloid A-LDL (SAA-LDL) and 1-antitrypsin-LDL (AT-LDL), were identified; however, the significance of SAA-LDL and AT-LDL as cardiovascular risk markers is unknown. Methods: We carried out a cross-sectional study involving 243 patients, and determined serum levels of SAA-LDL and AT-LDL. Results: Both serum levels of SAA-LDL and AT-LDL were significantly increased in current compared to non-current smokers. Stepwise regression analysis revealed that the current smoking status and duration of smoking were strong independent determinants of the AT-LDL level. In contrast, high-sensitivity C-reactive protein was the strongest determinant of the SAA-LDL level. In multiple logistic regression analysis, the current smoking status was most closely associated with the AT-LDL level. Successful SC employing a 12-week program significantly increased the body mass index and serum levels of obesity-related markers. Notably, successful SC significantly decreased levels of AT-LDL, but not those of SAA-LDL. Conclusions:The present study provides the first evidence for the distinct characteristics of two novel, oxidatively modified LDL markers, SAA-LDL and AT-LDL. In contrast to SAA-LDL, an inflammatory marker, AT-LDL serves as a marker of smoking-specific oxidative stress. These findings warrant further investigations to clarify if AT-LDL provides a key link between smoking and cardiovascular diseases.

show abstract

“…In the QCA measurements, lesion length tended to be longer in the low MDA-LDL group than in the high MDA-LDL group, but the difference was not statistically significant (pre-PCI lesion length: 21.3±19. 4 …”

Section: Ivus Findingsmentioning

confidence: 99%

Impact of Malondialdehyde-Modified Low-Density Lipoprotein on Tissue Characteristics in Patients With Stable Coronary Artery Disease　– Integrated Backscatter-Intravascular Ultrasound Study –

Ikenaga

Kurisu

Kono

et al. 2016

Circ J

View full text Add to dashboard Cite

Circulating malondialdehyde modified LDL is a biochemical risk marker for coronary artery disease

Cited by 55 publications

References 5 publications

Trimethylamine N-oxide and Risk Stratification after Acute Myocardial Infarction

Trimethylamine N-oxide and Risk Stratification after Acute Myocardial Infarction

α1-Antitrypsin Low-Density-Lipoprotein Serves as a Marker of Smoking-Specific Oxidative Stress

Impact of Malondialdehyde-Modified Low-Density Lipoprotein on Tissue Characteristics in Patients With Stable Coronary Artery Disease　– Integrated Backscatter-Intravascular Ultrasound Study –

Contact Info

Product

Resources

About

Circulating malondialdehyde modified LDL is a biochemical risk marker for coronary artery disease

Cited by 55 publications

References 5 publications

Trimethylamine N-oxide and Risk Stratification after Acute Myocardial Infarction

Trimethylamine N-oxide and Risk Stratification after Acute Myocardial Infarction

α1-Antitrypsin Low-Density-Lipoprotein Serves as a Marker of Smoking-Specific Oxidative Stress

Impact of Malondialdehyde-Modified Low-Density Lipoprotein on Tissue Characteristics in Patients With Stable Coronary Artery Disease – Integrated Backscatter-Intravascular Ultrasound Study –

Contact Info

Product

Resources

About

Impact of Malondialdehyde-Modified Low-Density Lipoprotein on Tissue Characteristics in Patients With Stable Coronary Artery Disease　– Integrated Backscatter-Intravascular Ultrasound Study –